Semiconductors Look Dangerously Overheated After Massive Run: Analyst

After a 13-day NASDAQ rally, BTIG's Jonathan Krinsky analyzes market risks and shares where to find better risk-reward opportunities today.

RBC Capital Reiterates Underperform on Pfizer, Maintains $25 Price Target

RBC Capital analyst Trung Huynh reiterates Pfizer (NYSE:PFE) with a Underperform and maintains $25 price target.

Astellas And Pfizer Announce FDA Grants Priority Review To sBLA For Perioperative PADCEV, In Combination With PD-1 Inhibitor Keytruda Or Keytruda QLEX As Treatment For Patients With MIBC; PDU

Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trialBuilding on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if

Compass Pathways Cheers Trump Order To Accelerate Access To Psychedlic Drug Treatements: 'Recognizes Profound Urgency Of Mental Health Crisis'

Compass Pathways said a White House executive order may speed FDA review of its psilocybin therapy COMP360 for treatment-resistant depression trials.

Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment

On Saturday, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration to move faster on reviews tied to psychedelic-based research and treatment, including ibogaine that veteran advocates say may help post-traumatic stress disorder.

4 Health Care Stocks With Whale Alerts In Today's Session

FDA Takes Step Forward on Testosterone Therapy for Men

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Trump Administration Eyes Former Deputy Surgeon General To Lead CDC After Months Of Turmoil: Report

Trump administration reportedly considers Erica Schwartz to lead CDC, pending final approval.

UBS Maintains Neutral on Pfizer, Raises Price Target to $27

UBS analyst Michael Yee maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $25 to $27.

Elon Musk Questions COVID-19 Vaccine Dosage, Says It Was 'Obviously Too High'

Elon Musk raises concerns over COVID-19 vaccine dosage, citing a severe reaction that nearly led to hospitalization.